Best Available Therapy (BAT) clinical trials
3 indexed studies · 0 currently recruiting
- Active not recruitingPHASE3
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
This study looks at a new drug, navitoclax, combined with ruxolitinib, or navitoclax alone, for adults with myelofibrosis whose previous treatment didn't work. It compares these to standard care to see how they affect spleen size and safety.
For: Myelofibrosis (MF)United States · Australia · Austria - Active not recruitingPHASE3
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study is testing a new medicine, axatilimab, for people in the UK aged 12 and over with chronic graft-versus-host-disease (cGVHD) that hasn't improved with other treatments. It compares axatilimab to other standard therapies to see if it works better.
For: Chronic Graft-versus-host-diseaseAustria · Belgium · Czechia - Active not recruitingPHASE3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
This study is testing a new medication called imetelstat for people with myelofibrosis, a rare bone marrow cancer, who haven't responded well to previous treatments. It compares imetelstat to other available therapies to see if it improves how long people live.
For: MyelofibrosisUnited States · Argentina · Australia